key: cord-0744808-lenr19eq authors: Angel, Miraclin T; Aaron, Sanjith; Sivadasan, Ajith; Benjamin, Kenneth; Harshad, Vanjare; Nair, Shalini; Abhilash, KPP; AT, Prabhakar; Mathew, Vivek title: Management and outcomes of COVID – 19 associated Cerebral Venous Sinus Thrombosis date: 2022-01-10 journal: J Stroke Cerebrovasc Dis DOI: 10.1016/j.jstrokecerebrovasdis.2022.106306 sha: 678ed7494f2d3065e256956bdd77e8e8df0cd02b doc_id: 744808 cord_uid: lenr19eq BACKGROUND: Systemic hyper-coagulabilty leading to micro and macro thrombosis is a known complication of Coronavirus disease – 2019(COVID -19). The postulated mechanism appears to be the viral activation of endothelium, triggering the coagulation pathways. Thrombosis of the cerebral veins and sinuses (CVT), a potentially serious condition, has been increasingly reported with COVID – 19 infection. In this clinical study we attempt to describe the clinical profile, investigations and outcomes of patients with COVID- 19 associated CVT. METHODS: This is a single centre prospective observational study from South India. The study included patients (aged >18 years) with concomitant COVID infection and CVT. The clinical, laboratory, imaging characteristics, management and outcomes were described and compared with COVID negative CVT patients. RESULTS: Out of 97 cases of CVT treated at our centre during the first and second waves of the COVID pandemic 11/97 (11%) were COVID related CVT. Among these 11 patients, 9 (81%) had presented with only CVT related symptoms and signs and were tested positive for COVID - 19 infection during the pre-hospitalization screening. Respiratory symptoms were absent in 90% of the patients. Headache (100%) and seizures (90%) were the common presenting symptoms. The median time to diagnosis was 6 hours from presentation to the emergency department. Transverse sinus was involved 10/11 (90%) and majority of them (9/11) had Haemorrhagic Venous Infarction (HVI). Acute inflammatory markers were elevated in comparison with non COVID CVT patients, with the mean serum D-dimer (2462.75ng/ml) and the C-reactive protein (64.5 mg/dl). Three patients (30%) underwent decompressive hemicraniectomy (DHC) because of large hemispheric HVI. All patients survived in the COVID CVT group while the mortality in the non COVID group was 4%. At 6 months follow up excellent outcome (modified Rankin Scale (mRS) score of 0–2) was noted equally in both groups. CONCLUSIONS: Symptoms and signs of CVT may be the only presentation of COVID-19 infection. Prompt recognition and aggressive medical management including DHC offers excellent outcomes. had presented with only CVT related symptoms and signs and were tested positive for COVID -19 infection during the pre-hospitalization screening. Respiratory symptoms were absent in 90% of the patients. Headache (100%) and seizures (90%) were the common presenting symptoms. The median time to diagnosis was 6 hours from presentation to the emergency department. Transverse sinus was involved 10/11 (90%) and majority of them (9/11) had Haemorrhagic Venous Infarction (HVI). Acute inflammatory markers were elevated in comparison with non COVID CVT patients, with the mean serum D-dimer (2462.75ng/ml) and the C-reactive protein (64.5 mg/dl). Three patients (30%) underwent decompressive hemicraniectomy (DHC) because of large hemispheric HVI. All patients survived in the COVID CVT group while the mortality in the non COVID group was 4%. At 6 months follow up excellent outcome (modified Rankin Scale (mRS) score of 0-2) was noted equally in both groups. Conclusions: Symptoms and signs of CVT may be the only presentation of COVID-19 infection. Prompt recognition and aggressive medical management including DHC offers excellent outcomes. COVID-19, Cerebral venous thrombosis, Decompressive hemicraniectomy Since March 11, 2020, the world has been grappled by the pandemic caused by the novel severe acute coronavirus -2(SARS-CoV2) with varied system-specific manifestations and guarded outcomes. Thrombotic complications have been increasingly reported in critically ill COVID patients (1) . This virus stands unique in comparison to other respiratory viruses, in view of its direct infection of endothelial cells with abnormal macrophage activation, and recruitment of peri-vascular T-cell infiltrates causing endothelial and inflammatory cell death, thrombotic microangiopathy, and angiogenesis (1) . This seems to be potentiated by a state of hypercoagulability caused by increased concentrations of coagulation factors, acquired antiphospholipid antibodies, and decreased concentrations of endogenous anticoagulant proteins (2) . Cerebral venous sinus thrombosis (CVT) as a presenting symptom in COVID-19 disease was first reported by Hughes et al in April 2020(3). Since then, there have been multiple case reports and case series published, describing the occurrence of CVT in context with infection as well as with vaccination. Despite the best management, the mortality remains high, which ranges from 20% -40%, making this a neurological complication which calls for a prompt identification and initiation of early aggressive management (4) (5) (6) . In this short report, we present our experience in management of patients with COVID-19 associated CVT, across the two waves of the pandemic (2020 -2021), describing the clinical presentation, the thrombotic derangements, management and outcomes in these patients and comparing them with the non COVID CVT patients managed during the same time period. To the best of our knowledge, this is the first report on outcomes, post decompressive hemicraniectomy (DHC) among patients with COVID -19 associated CVT. The study was conducted in Christian Medical College, Vellore a tertiary care referral Centre in South India. Patients aged 18 years or above with recent COVID-19 infection, confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR) assay of a nasopharyngeal swab for COVID-19, were included. The diagnosis of CVT was confirmed by magnetic resonance imaging with venography (MRI and MRV). CVT patients with confirmed COVID -19 were taken as cases, and CVT patients who were tested negative and treated during the same period were taken as controls. The risk factors, clinical features, laboratory findings, radiological findings, COVID-19 disease status, and data on management and outcomes for all patients were described and compared between the cases and controls. The primary outcome was the mortality rate and proportion with good functional outcome at discharge as defined as a score of ≤ 2 in the Modified Rankin' disability scale (mRS). History of COVID vaccination was noted and any vaccine associated CVT cases were excluded. There were 2 waves of pandemic in India, the first wave peaked between September -October 2020, the second being in March -April 2021. About 52 cases of CVT were admitted during the first wave, and about 45 cases were hospitalized during the second wave. Among these, 11 patients had concomitant COVID infection and CVT. The mean age appeared to be the third decade with male preponderance. Antecedent thrombotic risk factors were less in both the cases and controls. All of them reported headache and seizures were more common in the COVID group. CVT as an index presentation of COVID -19 was seen in 81% (n=9). Typical influenza like illness (ILI) was reported only in 2 patients with COVID positivity. One patient was critically ill with acute respiratory distress syndrome requiring mechanical ventilation. About 11 patients in the non COVID group reported respiratory symptoms, however they were tested negative. Hemorrhagic venous infarction (HVI) was seen in 81% in the COVID positive group vs. 40% in the COVID negative group and in both the groups it predominantly involved the temporal lobe. The COVID positive patients expressed higher inflammatory markers, aPL antibody positivity and thrombotic markers, which was statistically significant when compared to the non COVID controls. The clinical, laboratory, imaging characteristics with outcomes are tabulated in table 1. The median time of symptoms prior to presentation was 5 days (IQR 2 -10). The median time to diagnosis of CVT, from the time of presentation to emergency department was 6 hours (IQR 4 -28). All patients were treated with therapeutic anticoagulation, anti-epileptic drugs and antiedema measures with oral acetazolamide and hypertonic saline infusions. Three patients underwent emergency DHC in the COVID group as opposed to 5 patients in the non -COVID group, within 24 hours of presentation. There was no mortality in our cohort of COVID positive group, all patients improved on therapy, and were discharged, however 3 patients died in the non COVID group at discharge, and 1 more at 3 month follow-up. This study is one among the large case series from a single centre, involving the Indian population with COVID 19 and CVT. Our Centre, a quaternary care referral hospital in South India, deals with high burden of patients presenting with CVT(7). It is striking to note that the CVT was the presenting symptom for COVID -19, and the classical ILI symptoms were seen only in 2 patients. We could have missed out diagnosing COVID infection in the remaining, but for the institutional policy of admission only after screening for COVID infection during the pandemic period. Hameed et al in their case series, had 55% having ILI symptoms (5) . In a systematic review and meta-analysis by Baldini et al including 57 cases from 28 reports, 92.9% were symptomatic for COVID -19 with 81% having abnormal lung imaging and in 90% of the cohort, CVT occurred with/after symptom onset (4) . High prevalence of Antiphospholipid antibodies(aPL) have been reported in hospitalized COVID patients(73.3%) (8) . In a systematic review and metanalysis by M Taha et al, the nearly half of patients with COVID-19 were positive for one of the aPL, most frequently reported aPL being lupus anticoagulant (9) . They occur more frequently reported in critically ill patients and were not significantly associated with disease outcomes like venous thrombosis, invasive ventilation and mortality. Similarly, in our series the presence of aPL antibodies, decreased protein C, activated protein C resistance (APCR) and elevated factor 8 levels might be a consequence of endothelial activation and inflammation. The most salient finding in this study is the outcomes, which includes no mortalities in the COVID group and 4% in the non COVID group with good functional outcomes at discharge and at 6 month follow-up. This could be partly due to rapidity in diagnosis anterior circulation infarction, where 3 were discharged and mortality rates exceed 33% (10, 11) . Our previous experience in DHC among patients with CVT, have proven to have excellent outcomes (12) . Similarly prompt decision to DHC in the 3 patients in COVID cohort, within 24 hours of admission has resulted in good functional outcomes in 2 patients. The patient, who continued to be with persistent low sensorium, had other comorbidities like HIV infection and diabetes which might have contributed to the morbidity despite the aggressive management. CVT could be the index presentation of COVID 19 infection without the presence of ILI symptoms. COVID-19 testing should be included as standard workup for all CVT patients as 11% of CVT cases treated during the pandemic were related to COVID; also all COVID-19positive patients with headache and neurological symptoms should be evaluated for CVT. Prompt recognition with aggressive medical management alleviates mortality. DHC should be offered, if required early into the course of illness, despite a positive test for COVID -19. There was no specific funding obtained for the conduct of the study. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 Pathogeny of cerebral venous thrombosis in SARS-Cov-2 infection: Case reports. Medicine (Baltimore) Cerebral Venous Sinus Thrombosis as a Presentation of COVID-19 Cerebral venous thrombosis and severe acute respiratory syndrome coronavirus-2 infection: A systematic review and meta-analysis Cerebral Venous Thrombosis Associated with COVID-19 Infection: An Observational, Multicenter Study Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases Cerebral venous thrombosis, seasonal trends, and climatic influence: A regionspecificstudy Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review. RMD Open COVID-19 and Decompressive Hemicraniectomy for Acute Ischemic Stroke Decompressive hemicraniectomy for acute ischemic stroke associated with coronavirus disease 2019 infection: Case report and systematic review Decompressive craniectomy in cerebral venous thrombosis: a single centre experience We acknowledge all healthcare professionals involved in patient care during the pandemic period.